The news: Pushed by consumer demand and a shortage of the brand-name GLP-1 medications, WeightWatchers (WW) has joined a growing list of companies that will be offering compounded semaglutide (marketed by Novo Nordisk as Ozempic and Wegovy) to its members.
Last year, WW entered theweight loss drug market when it acquired Sequence, a telehealth company that prescribes the meds.
Starting at $189 per month, the new offering is an add-on to WW’s existing weight management program, which includes access to clinicians, dieticians, and treatments.
Shares of WW soared ~50% following the announcement, but are still down nearly 80% for the year.
